Generic Drugs

Savient launches authorized generic of oxandrolone tablets with Watson Pharmaceuticals

Published in Lab Law Weekly, February 2nd, 2007

Savient Pharmaceuticals, Inc. (SVNT) announced that Watson Pharmaceuticals (WPI), under the terms of its previous supply and distribution agreement with Savient, has launched an A-B rated authorized generic of oxandrolone tablets, USP (C-III), an Oxandrin brand equivalent product manufactured and supplied through Savient.

The authorized generic product will be distributed by Watson in both the 2.5 mg and 10 mg dosages. The A-B rated authorized generic of oxandrolone tablets will continue to meet all quality control standards of the Oxandrin brand and will contain the same active and inactive pharmaceutical ingredients. Oxandrin is Savient's oral anabolic agent for the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Law Weekly

Source: Lab Law Weekly (2007-02-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry